Meeting
2023 ASCO Annual Meeting
Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.
Authors
Genevieve MacAulay Vacheresse
University of Ottawa, Ottawa, ON, Canada
Genevieve MacAulay Vacheresse , Elham Sabri , Sheryl Domingo , Tien Le
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5578)
DOI
10.1200/JCO.2023.41.16_suppl.5578
Abstract #
5578
Poster Bd #
273
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
First Author: Mansoor Raza Mirza
Poster
2022 ASCO Annual Meeting
Trends in frontline PARP inhibitor maintenance in advanced epithelial ovarian cancer across the United States.
First Author: Erica Huelsmann
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).
First Author: Vivek Narayan
Poster
2022 ASCO Annual Meeting
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
First Author: JUNG-YUN LEE